A 3D Collagen-Based Bioprinted Model to Study Osteosarcoma Invasiveness and Drug Response.
bioprinting
cell proliferation
cisplatin resistance
collagen-based hydrogels
osteosarcoma
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
28 Sep 2022
28 Sep 2022
Historique:
received:
11
08
2022
revised:
21
09
2022
accepted:
23
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
The biological and therapeutic limits of traditional 2D culture models, which only partially mimic the complexity of cancer, have recently emerged. In this study, we used a 3D bioprinting platform to process a collagen-based hydrogel with embedded osteosarcoma (OS) cells. The human OS U-2 OS cell line and its resistant variant (U-2OS/CDDP 1 μg) were considered. The fabrication parameters were optimized to obtain 3D printed constructs with overall morphology and internal microarchitecture that accurately match the theoretical design, in a reproducible and stable process. The biocompatibility of the 3D bioprinting process and the chosen collagen bioink in supporting OS cell viability and metabolism was confirmed through multiple assays at short- (day 3) and long- (day 10) term follow-ups. In addition, we tested how the 3D collagen-based bioink affects the tumor cell invasive capabilities and chemosensitivity to cisplatin (CDDP). Overall, we developed a new 3D culture model of OS cells that is easy to set up, allows reproducible results, and better mirrors malignant features of OS than flat conditions, thus representing a promising tool for drug screening and OS cell biology research.
Identifiants
pubmed: 36236019
pii: polym14194070
doi: 10.3390/polym14194070
pmc: PMC9571197
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : IG 2019 - ID. 22805
Références
Cancer Immunol Immunother. 2021 Sep;70(9):2617-2624
pubmed: 33580363
Lancet Oncol. 2020 Mar;21(3):446-455
pubmed: 32078813
J Chemother. 2001 Jun;13(3):324-30
pubmed: 11450892
Clin Cancer Res. 2014 Aug 15;20(16):4200-9
pubmed: 24803583
J Mater Sci Mater Med. 2019 Mar 6;30(3):32
pubmed: 30840132
Semin Cancer Biol. 2022 Mar 21;86(Pt 3):224-236
pubmed: 35331851
Front Immunol. 2022 Jun 01;13:907550
pubmed: 35720360
Curr Opin Cell Biol. 2010 Oct;22(5):697-706
pubmed: 20822891
Pharmacogenomics. 2016 Dec;17(18):2097-2114
pubmed: 27883291
Mol Biol Rep. 2021 Sep;48(9):6525-6538
pubmed: 34379286
Appl Phys Rev. 2018 Dec;5(4):041109
pubmed: 32550961
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Lancet Oncol. 2016 Oct;17(10):1396-1408
pubmed: 27569442
Cancer Res. 2008 Aug 15;68(16):6661-8
pubmed: 18701490
Br J Cancer. 1975 Jul;32(1):87-107
pubmed: 1058038
Exp Biol Med (Maywood). 2022 Feb;247(4):310-316
pubmed: 35043695
Biomaterials. 2022 Jun 20;287:121639
pubmed: 35779481
Front Oncol. 2020 Mar 10;10:331
pubmed: 32211337
Eur J Cancer. 2001 Apr;37(6):760-6
pubmed: 11311651
Future Oncol. 2017 Feb;13(4):357-368
pubmed: 27651036
J Clin Oncol. 2015 Jul 10;33(20):2279-87
pubmed: 26033801
Bioact Mater. 2022 Mar 29;18:459-470
pubmed: 35415297
ACS Appl Mater Interfaces. 2022 Jul 6;14(26):29467-29482
pubmed: 35735173
J Clin Oncol. 1988 Feb;6(2):329-37
pubmed: 2448428
Cancers (Basel). 2018 Dec 06;10(12):
pubmed: 30563275
Int J Cancer. 2017 Dec 1;141(11):2305-2317
pubmed: 28815582
Adv Healthc Mater. 2022 Jul 22;:e2200690
pubmed: 35866252
Materials (Basel). 2021 Jun 24;14(13):
pubmed: 34202765
Cancers (Basel). 2021 Feb 08;13(4):
pubmed: 33567616
J Transl Med. 2019 Sep 14;17(1):309
pubmed: 31521169
Int J Bioprint. 2020 Apr 21;6(3):270
pubmed: 33088985
Front Genet. 2020 Feb 25;11:52
pubmed: 32161615
PLoS One. 2015 Mar 30;10(3):e0122500
pubmed: 25822731
Eur J Cancer. 2020 Jan;125:58-68
pubmed: 31838406
Acta Biomater. 2022 Apr 1;142:208-220
pubmed: 35167953
Cancers (Basel). 2022 Jan 04;14(1):
pubmed: 35008401
Transl Oncol. 2021 Apr;14(4):101015
pubmed: 33493799